Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 2Lymphoid 2Plasma cell 1Other hematologic neoplasm 1Gastrointestinal 1Dermatologic 1

Conditions

Lymphoma 1Colonic Neoplasms 1

Interventions

Oxaliplatin 1439Fluorouracil 1319Capecitabine 1114Gemcitabine 1057Leucovorin 939Bevacizumab 847Irinotecan 830Cisplatin 676Radiotherapy 560Cetuximab 482pembrolizumab 435Paclitaxel 401Drug Therapy 358Nivolumab 350130-nm albumin-bound paclitaxel 328Docetaxel 290Sorafenib 288S 1 (combination) 279Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 257lenvatinib 222sintilimab 218tislelizumab 214durvalumab 212regorafenib 209Magnetic Resonance Spectroscopy 205apatinib 204Radiosurgery 204Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
methoxyamine × Gastrointestinal × Clear all
NCT01851369 2024-05-08

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
93 enrolled 27 charts
GastrointestinalLymphoid

Colonic Neoplasms, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡